correction:[Ip-health] IFPMA: WHA Resolution Recognizes IP
is Important Incentive for Development
of New Health-Care Products
Michelle Childs
michelle.childs@cptech.org
Thu Jun 1 16:51:02 2006
As has been helpfully pointed out IFPMA have official relations with WHO.
This means that the preceding para of the resolution applies (4.2).
However the point remains : this para grants observer status, not joint
parity with Member States.
Michelle
<SNIP> '4(2) to invite, as observers at the sessions of the
intergovernmental working group, representatives of non-Member States, of
liberation movements referred to in resolution WHA27.37, of organizations
of the United Nations system, of intergovernmental organizations with
which WHO has established effective relations, and of nongovernmental
organizations in official relations with WHO, who shall attend the
sessions of the working group in accordance with the relevant Rules of
Procedure and resolutions of the Health Assembly;'
> It is interesting to note that IFPMA is inaccurate in its portrayal of
its role in the working group. It states below that it will '
representing
> the pharmaceutical industry in the joint development of this strategy,
along with WHO Member States and other stakeholders.
>
> The resolution makes it very clear that the responsibility for drawing
up
> the strategy is with Member States , it is not a joint development with
private entities.
>
> The resolution provides only for a very limited role for trade bodies
and
> others and stresses the need to avoid conflicts of interest:
>
> < snip> 3) to invite experts and a limited number of concerned public
and
> private entities to attend the sessions of the intergovernmental working
group and to provide advice and expertise, as necessary, upon request of
the Chair, taking into account the need to avoid conflicts of interest;
>
> Michelle
>
>
>
>
>> http://www.ifpma.org/News/NewsReleaseDetail.aspx?nID=3D5022
>> World Health Assembly Resolution Recognizes IP is Important Incentive
for Development of New Health-Care Products
>> IFPMA
>> Geneva, 5/31/2006 - The IFPMA notes positively the 59th World Health
Assembly Resolution (A59/A/Conf. Paper No. 8, 27 May 2006) on
>> =93Innovation, essential health research and intellectual property
rights:
>> towards a global strategy and plan of action=94 and the establishment of
an intergovernmental working group =93to draw up a global strategy and plan
of action=85 to address essential health research and development relevant
to diseases that disproportionately affect developing
>> countries.=94 The IFPMA looks forward to representing the pharmaceutical
industry in the joint development of this strategy, along with WHO Member
States and other stakeholders.
>> Dr. Harvey Bale, Director General of the IFPMA, noted: =93As it did with
the Commission on Intellectual Property Rights, Innovation and Public
Health, so the IFPMA will work actively in this new WHO project. It is
important for patients worldwide that, in the coming two years, the WHO
can identify positive measures that reflect the growing recognition of the
benefits from the adoption of effective intellectual property
systems across the globe.=94
>> As the WHA Resolution itself notes, there is indeed global recognition
=93that intellectual property rights are an important incentive for the
development of new health-care products=94 and that =93considerable
progress
>> has been made in recent years by governments, industry, charitable
foundations and non-governmental organizations in initiatives to
develop
>> new products to fight diseases affecting developing countries and to
increase access to existing ones=94.
>> Dr. Bale stated: =93We also recognize that in certain disease areas wher=
e
developing countries are most highly impacted, further efforts are needed
to create new partnerships to carry forward research and
development.=94 In addition to its many medicines access partnerships, the
>> pharmaceutical industry itself is collaborating in a large number of
important =93neglected disease=94 projects, as confirmed by two recent repo=
rts
from the London School of Economics & Political Science; The New
>> Landscape of Neglected Disease Drug Development 1 and The IFPMA Health
Partnerships Survey: A Critical Appraisal 2. Industry-led partnerships to
improve both access and R&D are also documented in detail in a new IFPMA
publication: Partnerships to Build Healthier Societies in the Developing
World 3.
>> In summary, the research-based pharmaceutical industry will contribute
actively to the upcoming two year WHO intergovernmental working group.
About the IFPMA
>> The International Federation of Pharmaceutical Manufacturers &
>> Associations is a non-profit, non-governmental organisation
representing
>> national industry associations and companies from both developed and
developing countries. Member companies of the IFPMA are research-based
pharmaceutical, biotech and vaccine companies.
>> For More Information Please Contact
>> Guy Willis
>> Director of Communications, IFPMA
>> Ch. Louis-Dunant, 15
>> P.O. Box 195
>> 1211 Geneva 20, Switzerland
>> Email: g.willis@ifpma.org
>> Tel: +41 (22) 338 32 00
>> Fax: +41 (22) 338 32 99
>> _______________________________________________
>> Ip-health mailing list
>> Ip-health@lists.essential.org
>> http://lists.essential.org/mailman/listinfo/ip-health
>
>
> --
> Michelle Childs -Head of European Affairs
> Consumer Project on Technology in London
> 24, Highbury Crescent, London, N5 1RX,UK.
> Tel:+44(0)207 226 6663 ex 252.
> Mob:+44(0)790 386 4642. Fax: +44(0)207 354 0607
> http://www.cptech.org
>
> Consumer Project on Technology in Washington, DC
> 1621 Connecticut Ave, NW, Washington, DC 20009 USA .Tel.:
> +1.202.332.2670,Fax: +1.202.332.2673
>
> Consumer Project on Technology in Geneva
> 1 Route des Morillons, CP 2100, 1211 Geneva 2, Switzerland
> Tel: +41 22 791 6727
>
>
>
>
--
Michelle Childs -Head of European Affairs
Consumer Project on Technology in London
24, Highbury Crescent, London, N5 1RX,UK.
Tel:+44(0)207 226 6663 ex 252.
Mob:+44(0)790 386 4642. Fax: +44(0)207 354 0607
http://www.cptech.org
Consumer Project on Technology in Washington, DC
1621 Connecticut Ave, NW, Washington, DC 20009 USA .Tel.:
+1.202.332.2670,Fax: +1.202.332.2673
Consumer Project on Technology in Geneva
1 Route des Morillons, CP 2100, 1211 Geneva 2, Switzerland
Tel: +41 22 791 6727
--
Michelle Childs -Head of European Affairs
Consumer Project on Technology in London
24, Highbury Crescent, London, N5 1RX,UK.
Tel:+44(0)207 226 6663 ex 252.
Mob:+44(0)790 386 4642. Fax: +44(0)207 354 0607
http://www.cptech.org
Consumer Project on Technology in Washington, DC
1621 Connecticut Ave, NW, Washington, DC 20009 USA .Tel.:
+1.202.332.2670,Fax: +1.202.332.2673
Consumer Project on Technology in Geneva
1 Route des Morillons, CP 2100, 1211 Geneva 2, Switzerland
Tel: +41 22 791 6727